Helsinki, Finland · Founded 2013 · Privately Held (backing)
Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. TILT Biotherapeutics is based in Helsinki, Finland and was founded in 2013. Its last reported valuation was $100 million in Jun 2024. It has raised $82 million.
Last reported valuation
$100.2M
Oct 2026
Priced at
—
Total raised
$82.0M
Last round
—
Cap table — not yet on record
TILT Biotherapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of TILT Biotherapeutics with a free account
·The complete investor list: 14 names
·Watch TILT Biotherapeutics: the Monday email on marks, rounds and moves
